Given the success of antibody–drug conjugates (ADCs; reviewed in [90]) harbouring a DNA topoisomerase I (TOP1) inhibitor warhead in breast cancer [91], and the known synergistic interaction between TOP1 inhibitors and PARPi [92], combinations of TOP1i-ADCs with PARPi should also be considered. This evidence concerns the gene TOP1 and breast carcinoma.